HMH Holding’s CFO Thomas McGee and CEO Eirik Bergsvik bought $1.74M of $HMH stock on Nov 17 and 18, at prices about 30% below the $16.66 close before Q3 results. McGee bought 140,000 shares worth $1.65M, and Bergsvik bought 8,000 shares worth $88,080.
Full-year adjusted EBITDA guidance of @HMHGlobal was cut to $135M-$140M because of Middle East disruption and delayed equipment orders, but orders rose 12% and management expects floater activity to rise 10-25% in 2027.
109
The Chairman and two Directors of Kodiak Gas Services bought $993,816 of stock within a week of a record Q3 and a raised full-year outlook.
Chairman Randall Hogan bought 11,500 $KGS shares at $42.953 on Nov 17, worth $493,961, taking his holding to 42,041 shares, Director Alex Darden bought 10,000 shares at $44.99 on Nov 11, worth $449,900, and Director Gretchen Holloway bought 1,145 shares at $43.629 on Nov 12, worth $49,955.
@KodiakGasSrvs’ Q3 revenue grew 25% to $401.8M, adjusted EBITDA hit a record $224.5M, fleet utilisation reached 98.3%, and full-year adjusted EBITDA guidance rose to $840M-$860M. The quarterly dividend was raised 4.1% to $0.51 per share.
135
CG Oncology’s Chairman and CEO Arthur Kuan and Chief Commercial Officer Isabel Kalofonos, who joined recently, both bought stock on Nov 18, two days after positive Phase 3 data. Combined: about $2.67M.
Kuan bought 30,000 $CGON shares at $78.88, worth $2.37M, lifting his holding to 228,916 shares, and Kalofonos opened her first position with 3,751 shares at $79.755, worth $299,161.
The PIVOT-006 trial of @cgoncology showed that cretostimogene cut bladder cancer recurrence risk by 68% (hazard ratio 0.32, p<0.0001) with no Grade 3 or higher treatment-related adverse events, and a BLA submission is planned for Q2 2027.
163
PureCycle Technologies’ CEO Dustin Olson and Director Fernando Musa bought $470,296 of stock in the two weeks after a Q3 report that missed expectations.
Olson bought 220,000 $PCT shares at $1.69, worth $371,800, and Musa bought 57,600 shares at $1.71, worth $98,496.
@PureCycleTech Q3 revenue fell to $2.3M from $4.5M because of plant reliability issues and a New Jersey deadline extension. Management says the issues are resolved, production rose 14% sequentially, and liquidity stands at $193M.
298
Bullish signal at Forgent $FPS: Executives and a director buy shares totaling $1.08M following strong results and raised guidance.
Story here:
2iqresearch.com/blog/forgent…
1
191
Eight weeks after completing the Vylor spin-off, Corteva’s CEO and Chair are putting their own money into the standalone crop protection company.
Luke Kissam bought $300,312 of $CTVA stock on Nov 13 and Greg Page added $185,403 across two days, at prices near $9.30 against analyst targets of $15-$18.
Standalone Corteva carries about $7.5B in revenue and a dividend yield above 5%, and now, its leaders are buying.
169
Strong insider buying at America’s rare earth leader.
$3.35M cluster buy at $MP after operational progress.
Analysis:
2iqresearch.com/blog/3-35m-l…
3
279
Hornbeck Offshore Services’ President and CEO Todd Hornbeck bought $1.5M of stock across Nov 10 and 11, a week after the first quarterly results since the Helix merger.
He purchased 189,570 $HOS shares at $5.275, worth $999,981, and 91,296 shares at $5.477, worth $500,028.
On a combined basis, Q3 revenue was $503M with $155M of adjusted EBITDA, and the company has signed a five-year Shell agreement and targets $75M of annual synergies within three years.
1
144
Adtran Holdings’ Chairman and CEO Tom Stanton bought 150,000 $ADTN shares at $4.006, worth $600,900, and CFO Timothy Santo bought 17,820 shares at $4.163, worth $74,188, both on Nov 6.
@Adtran Q3 non-GAAP EPS of $0.09 beat the $0.03 consensus and optical revenue grew 11%, while revenue missed estimates only because supply constraints limited shipments.
171
Chairman and CEO of Rockwell Automation, Blake Moret, bought 4,000 $ROK shares at a weighted average of $386.36 on Nov 9, worth about $1.55M and lifting his holding to 99,285 shares, four days after the stock fell 14% on Q4 results.
Adjusted EPS rose 16% to $3.88 and beat the $3.69 consensus, and @ROKAutomation reached its 22% operating margin target three years early. The shares fell because revenue missed the $2.41B consensus and recurring revenue growth came in below expectations.
2
1
211
Galaxy Digital’s Founder and CEO Mike Novogratz bought $9.86M of $GLXY stock after the shares fell more than 40% in a month.
Novogratz purchased 760,000 Class A shares at an average of $12.979 on Nov 5, just above the 52-week low of $11.78.
He said there is a big gap between the share price and the value of the business, pointing to onchain finance and AI demand as long-term shifts.
Galaxy has also bought back 9.8 million shares, and its Helios campus in Texas has 800 MW under long-term contracts.
TFI International's Chairman, President and CEO Alain Bédard bought CAD $2.67M of $TFII stock on Nov 2, including 20,000 shares at CAD $132, and Directors Steven Mayer, John Pratt and Debra Kelly-Ennis added about CAD $705,500 more, all within days of a 17% post-earnings drop. Combined: approximately CAD $3.37M.
@tfiintl Q3 adjusted EPS rose nearly 40% to $1.67, Truckload operating income nearly doubled to $100M, and TFI posted a sub-90 operating ratio for the second consecutive quarter. The shares fell 17% because EPS missed the $1.75 consensus and US LTL remains weak.
1
193
Aberdeen Group's Chair Designate and two Directors bought £241,630 worth of $ABDN stock after Q3 sell-off.
- Torbjörn Magnusson (Chair Designate): 90,190 shares worth £200,197 on Oct 30.
- Arno Kitts (NE Director): 10,000 shares worth £22,038 on Oct 27.
- Katie Bickerstaffe (NE Director): 9,033 shares worth £19,395 on Oct 23.
Q3 AUMA of £578.9bn, interactive investor inflows up 32%, and full-year profit targets reaffirmed. Adviser outflows of £0.7bn remain the drag.
@Aberdeen_plc
163
Stewart Information Services' CEO, Chairman and three Directors all bought stock after Q3 earnings sent the shares to a 52-week low. Combined: $460,970.
Frederick Eppinger, CEO, bought 3,000 $STC shares at $44.45, worth $133,350. Chairman Thomas Apel and Directors Clifford Bradley Jr. and William Corey Jr. each added roughly $94,000 on Oct 23, and Director Deborah Matz opened a new position worth $43,910.
@StewartTitleCo's Q3 adjusted EPS of $1.33 missed estimates, and the shares fell about 17% in a week to near the 52-week low of $42.73. Insiders are buying in clusters as a show of confidence in recovery.
176
Telix Pharmaceuticals' Founder and CEO, Chairman and a Non-Executive Director all bought stock within days of each other after Q3 results. Combined: $751,448.
Christian Behrenbruch, Founder and CEO, bought 38,750 $TLX shares at A$12.894, worth $350,783. Chairman David Gill added $29,880 on Oct 23. Director William Jellison opened a new position worth $237,327.
@TelixPharma's Q3 revenue rose 19% to $245M, full-year guidance of $950M-$970M was maintained, insider buying at this time shows insider's belief that stock is underpriced.
2
259
At Gentherm, a newly appointed Director and the CEO both bought stock the day after Q3 results. Combined: $662,600.
Paul Mascarenas, Director, bought 20,000 $THRM shares at a weighted average of $26.63, worth $532,600. William Presley, CEO, bought 5,000 shares at $26.00, worth $130,000.
Mascarenas joined the @Gentherm board on Oct 1, the day the Modine Performance Technologies combination completed. Full-year product revenue guidance rose to $1.825B-$1.925B, and the company repurchased $60M of stock in October.
153
Positive clinical data + strong insider buying at Rapport Therapeutics $RAPP.
$1.56M cluster buy signals internal confidence in RAP-219. Analysis:
2iqresearch.com/blog/1-56-mi…
145
Cerillion's Founder and Non-Executive Director Guy O’Connor bought £138,000 of $CER stock at £6.90/share on Oct 21.
The @cerillion shares traded around £13.50 in early June, before a Sep 14 profit warning guided full-year revenue to £46M-£48M.
The company blamed delayed customer orders, while major implementations, including its largest-ever Omantel contract, continue to progress. Full-year results are due at the end of November.
Insider buy at this point after several years indicate that insider expects a strong recovery.
133
Strong conviction from the top at Applied Digital.
Founders invest $6.67M following recent AI infrastructure milestones. Analysis:
2iqresearch.com/blog/founder…
118
KITS Eyecare's Founder and CEO Roger Hardy bought CAD $774,950 of stock nine days after preliminary Q3 revenue grew 21.6% to a record.
Hardy purchased 50,000 $KITS shares at CAD $15.499 on Oct 16, worth USD $548,131. His stake now stands at 4,156,000 shares.
@kitseyecare Q3 revenue passed a $250M annualised run-rate for the first time, glasses revenue grew 59.3%, and the company holds $30.6M in cash with no debt.
102


